This study is an open label, non-randomized phase I single-armed study in women with
metastatic breast cancer (MBC) who have previously undergone all available standard
chemotherapy regimens. The purpose of the study is to estimate the pharmacokinetics (PK)
after single dose and multiple dose of BP-C1, investigate interleukin levels during BP-C1
treatment and assess treatment response according to RECIST criteria.